Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -218.65% is 143% below its 2-year average of -90.09%, near the low end of its 2-year range (-218.65%–-9.02%).
As of the fiscal period ended Tuesday, June 30, 2026. 119.81% below its 12-month average of -99.47%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -218.65%.
RETURN ON EQUITY (ROE)
-218.65%
RETURN ON EQUITY (ROE) AVG TTM
-99.47%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-119.81%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-420.48%
vs the sector median at left
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$7.07M
Return on Equity (ROE)
-218.65%
TTM Avg
-99.47%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.04M
Return on Equity (ROE)
-111.46%
TTM Avg
-348.97%
3Y Avg
-374.13%
5Y Avg
-408.25%
Market Cap
$7.12M
Return on Equity (ROE)
N/A
TTM Avg
-159.14%
3Y Avg
523.81%
5Y Avg
82.41%
Market Cap
$7.15M
Return on Equity (ROE)
-225.67%
TTM Avg
-236.53%
3Y Avg
-220.64%
5Y Avg
-186.37%
Market Cap
$7.19M
Return on Equity (ROE)
-370.16%
TTM Avg
-148.31%
3Y Avg
-87.53%
5Y Avg
-43.20%
Market Cap
$7.19M
Return on Equity (ROE)
N/A
TTM Avg
158.93%
3Y Avg
168.21%
5Y Avg
33.14%
Market Cap
$6.88M
Return on Equity (ROE)
-847.90%
TTM Avg
-134.62%
3Y Avg
-211.14%
5Y Avg
-242.56%
Market Cap
$7.31M
Return on Equity (ROE)
-1168.44%
TTM Avg
-606.51%
3Y Avg
-330.90%
5Y Avg
-270.23%
Market Cap
$6.74M
Return on Equity (ROE)
-227.37%
TTM Avg
-118.13%
3Y Avg
-87.25%
5Y Avg
-55.09%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $7.07M | -218.65% | -99.47% | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.04M | -111.46% | -348.97% | -374.13% | -408.25% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.12M | N/A | -159.14% | 523.81% | 82.41% |
| Longeveron Inc. (LGVN)vs › | $7.15M | -225.67% | -236.53% | -220.64% | -186.37% |
| Co-Diagnostics, Inc. (CODX)vs › | $7.19M | -370.16% | -148.31% | -87.53% | -43.20% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.19M | N/A | 158.93% | 168.21% | 33.14% |
| Exicure, Inc. (XCUR)vs › | $6.88M | -847.90% | -134.62% | -211.14% | -242.56% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -1168.44% | -606.51% | -330.90% | -270.23% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.74M | -227.37% | -118.13% | -87.25% | -55.09% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | -85.24% | 23.31% | -10.41% | -27.01% |
ROE
-218.7%
ROA
-206.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -218.65% |
| 2026-03-31 | -89.59% |
| 2025-12-31 | -37.66% |
| 2025-09-30 | -9.02% |
| 2025-06-30 | -142.43% |
| 2025-03-31 | -114.52% |
| 2024-12-31 | -71.82% |
| 2024-09-30 | -37.00% |
